We are live on ! Find out more
RCP

Rho Capital Partners Portfolio holdings

AUM $20.4M
This Fund
S&P 500
This Quarter Est. Return
+1.55%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$144M
AUM Growth
+$49.7M
Cap. Flow
+$49.1M
Cap. Flow %
34.04%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$55.1M

Top Sells

Rank Stock Value
1
TVRD
Tvardi Therapeutics
TVRD
+$5.86M
2
FSNN
Fusion Connect, Inc. Common Stock
FSNN
+$203K

Sector Composition

Rank Sector Weight
1 Healthcare 89.45%
2 Communication Services 10.55%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
1
Tvardi Therapeutics
TVRD
$23.6M
$70.3M 48.74%
90,779
-8,334
-8% -$5.86M
NGM
2
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$55.1M 38.25%
+3,766,667
New +$55.1M
LVO icon
3
LiveOne
LVO
$65.8M
$15.2M 10.55%
366,354
– –
MRSN
4
DELISTED
Mersana Therapeutics
MRSN
$3.23M 2.24%
31,858
– –
SENS icon
5
Senseonics Holdings Inc
SENS
$254M
$326K 0.23%
7,980
– –
FSNN
6
DELISTED
Fusion Connect, Inc. Common Stock
FSNN
– –
-155,069
Closed -$203K

Similar funds

LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

Rho Capital Partners's Q2 2019 Portfolio in Review

As of Q2 2019, Rho Capital Partners held 6 positions worth $144M, up 53% from $94.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Rho Capital Partners deployed $49.1M of net new capital in Q2 2019, opening 1 new position. Its largest new stake was NGM Biopharmaceuticals, Inc. Common Stock: 3,766,667 shares worth $55.1M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 79% a quarter earlier, followed by Communication Services and Industrials.

On the sell side, the largest reduction was Tvardi Therapeutics, an estimated $5.86M trimmed.

  • Rho Capital Partners's largest Q2 2019 buy was NGM Biopharmaceuticals, Inc. Common Stock: 3,766,667 shares worth $55.1M.
  • Rho Capital Partners's biggest Q2 2019 reduction was Tvardi Therapeutics, cutting an estimated $5.86M.
  • Rho Capital Partners fully exited Fusion Connect, Inc. Common Stock in Q2 2019, selling an estimated $203K.
  • Rho Capital Partners's ten largest holdings make up 100% of its $144M portfolio in Q2 2019.
  • Rho Capital Partners opened 1 new position and closed 1 in Q2 2019.
  • Rho Capital Partners's portfolio value rose 53% quarter-over-quarter to $144M.

Based on Rho Capital Partners's 13F filing for Q2 2019, filed 13 Aug 2019.